MedPath

Tolerance & Responsiveness Improvement for Metformin (TRIM)

Phase 4
Completed
Conditions
Type2 Diabetes Mellitus
Interventions
Registration Number
NCT03670043
Lead Sponsor
West Side Institute for Science and Education
Brief Summary

The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
29
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Metformin ERMetformin Extended Release Oral TabletThe subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)
PsylliumPsyllium powderThe subjects developing GI-related symptoms with metformin will be randomized to Psyllium
Primary Outcome Measures
NameTimeMethod
Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire3 months

This scale is based on symptoms that frequently occur in IBS cases, examines abdominal discomfort status, stool properties, and defecation feelings. The scale includes a total of 11 items, with 6 possible grades for each item that range from 0 points (never having this symptom) to 5 points (the symptom is always present). The total score is the sum of the scores for each item. The Total score is used. No "subscale" is used. Total range is minimum=0, maximum=55. The higher values represent a worse outcome.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Jesse Brown VA Medical Center

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath